Every year, the United States Food and Drug Administration’s National Youth Tobacco Survey (NYTS) provides one of the most closely watched snapshots of tobacco and nicotine use among young people. The survey plays an important role in informing regulatory discussions not only in the United States but also globally, as policymakers increasingly look to youth data when considering restrictions on emerging nicotine products.
The latest survey findings once again highlight a central public health concern: preventing nicotine uptake among young people remains an essential policy objective.
However, the data also raise a broader question that extends beyond the United States. How should governments interpret youth nicotine-use data, and how can policymakers protect young people while ensuring that regulation remains proportionate, evidence-based, and responsive to the different risk profiles of nicotine products?
The answer requires moving beyond headlines and recognising that youth protection and harm reduction are not mutually exclusive objectives.
Why Youth Data Matters
The use of nicotine products by young people deserves serious attention. Nicotine is addictive and may affect the developing brain, making youth prevention an essential public health objective. Governments therefore have legitimate reasons to monitor emerging nicotine products and implement measures that minimise youth access and uptake.
The latest 2025 National Youth Tobacco Survey (NYTS) found that 1.5% of U.S. middle and high school students reported using nicotine pouches in the past 30 days, representing approximately 420,000 students. While any youth nicotine use warrants attention, these findings indicate that nicotine pouch use remains relatively uncommon compared with several other nicotine product categories. Importantly, the survey does not support the conclusion that nicotine pouches are being used widely among young people or that they represent a dominant driver of youth nicotine use.
This context matters because prevalence data can sometimes be interpreted in ways that create unnecessary alarm. Effective public health policy should respond to the evidence presented by surveillance data while avoiding conclusions that extend beyond what the data demonstrate.
What Surveys Can and Cannot Tell Us
At the same time, youth surveys should be interpreted carefully.
Cross-sectional surveys provide valuable snapshots of behaviour at a particular moment in time, but they do not answer every policy question. They cannot establish long-term health outcomes, determine causation, or fully explain why behaviours change over time.
Similarly, prevalence figures alone do not always provide a complete picture.
Understanding public health implications often requires additional information, including patterns of frequency, regularity of use, transitions between products, and broader smoking trends within the population.
This does not diminish the importance of youth data. Rather, it highlights the importance of using survey findings as one component of a broader evidence base rather than treating any single dataset as the sole determinant of policy.
It is also important to distinguish between any past 30-day use and patterns of frequent or established use. The NYTS measures whether respondents used a product at least once during the previous 30 days, but this measure alone does not distinguish experimentation from regular use or nicotine dependence. Policymakers should therefore interpret prevalence estimates alongside other indicators, including frequency of use, transitions between products, smoking status, and longer-term behavioural trends.
Different Products, Different Risks
One of the challenges facing regulators is that modern nicotine markets have become increasingly diverse.
Cigarettes, e-cigarettes, nicotine pouches, heated tobacco products, and nicotine replacement therapies all contain nicotine but differ substantially in how nicotine is delivered and in their associated toxicological profiles.
The overwhelming burden of smoking-related disease remains driven primarily by combustion. Burning tobacco generates thousands of chemicals, including numerous carcinogens and toxicants associated with cancer, cardiovascular disease, and respiratory illness.
Not all nicotine products involve combustion or expose users to the same constituents.
Recognising these differences does not mean minimising concerns about youth uptake. Rather, it means acknowledging that nicotine products may occupy different positions on the risk continuum and that public health policy should consider both youth protection and relative risk.
Youth Protection and Harm Reduction Are Complementary Objectives
Public debates sometimes present policymakers with a false choice between protecting young people and supporting harm reduction for adults who smoke.
In reality, these objectives can and should coexist.
Strong age restrictions, retail compliance measures, responsible marketing practices, restrictions on youth-oriented branding, product standards, and effective enforcement mechanisms can all help minimise youth access.
At the same time, policies should also consider the needs of adults who continue to smoke combustible cigarettes, which remain the leading cause of tobacco-related disease and premature mortality.
Reducing smoking-related disease and preventing youth nicotine uptake are both legitimate public health objectives. Achieving one should not require abandoning the other.
The relatively low prevalence of nicotine pouch use reported in the NYTS should not be interpreted as a reason for complacency. Rather, it demonstrates that strong youth protections should be maintained while avoiding policy responses that assume levels of youth use not reflected in current surveillance data. Evidence-based regulation should respond proportionately to observed patterns of use rather than hypothetical scenarios.
The Importance of Proportionate Regulation
The latest FDA survey serves as an important reminder that youth nicotine use requires continued vigilance. At the same time, the findings show that past 30-day nicotine pouch use among U.S. youth remains relatively low at 1.5%, suggesting that current surveillance data should inform proportionate regulatory responses rather than fuel unnecessary concern about widespread youth uptake.
However, the appropriate response to youth data is not automatically to treat all nicotine products as equivalent or to assume that one policy approach should apply uniformly across fundamentally different product categories.
Evidence-based regulation requires a more nuanced approach.
Youth protection measures should remain robust and should continue evolving as markets change. At the same time, policymakers should recognise that products differ in their characteristics, patterns of use, and risk profiles.
Proportionate regulation does not imply deregulation. It means aligning policy interventions with available evidence while balancing multiple public health objectives simultaneously.
Looking Ahead
The FDA’s National Youth Tobacco Survey remains one of the world’s most important sources of information on youth tobacco and nicotine use. Its findings deserve careful attention and should continue informing efforts to prevent youth initiation and improve public health outcomes.
However, the survey also highlights a broader challenge confronting regulators around the world.
Modern nicotine markets are increasingly complex. Protecting young people, reducing smoking-related disease, and responding to product innovation require policies that are evidence-based, adaptable, and proportionate.
Youth protection and harm reduction should not be viewed as competing objectives.
The challenge for policymakers is developing frameworks capable of achieving both.
As governments continue to review nicotine regulation, the question is not whether young people should be protected. They should be.
The question is how best to protect young people while ensuring that regulation remains aligned with scientific evidence and responsive to the increasingly diverse realities of modern nicotine products.
Source
